Search PubMed⌕ Search

Biomedical subjects

T A Voronina

Publications and source records attributed to T A Voronina.

At least 19 recordsLinked to original sources
PubMed2006

[Antioxidants in complex treatment of Parkinson's disease].

Experimental and clinical study of mexidol efficacy in the complex therapy of Parkinson's disease has been carried out. It is shown that in a Parkinsonian animal model using oxotremorine, mexidol reduces Parkinsonian symptoms and decreases expression of neurophysiological changes caused by oxotremorine. Neurohistological study of substantia nigra neurons in a Parkinsonian model using MPTP revealed a neuroprotective effect of mexidol. An assignment of mexidol (4,0 ml intravenous in drops during 10 days) to patients with Parkinson's disease, receiving the basic therapy with antiparkinsonic drugs, reduced tremor, rigidity and bradykinesia. The most marked effect was observed in patients with prevalence of trembling symptoms at early stages of the disease. The results of clinical study have been confirmed by electromyographic and electroneuromyographic data.

Animals↗
PubMed2005

Neuroprotective activity of proproten in rats with experimental local photothrombosis of the prefrontal cortex.

Proproten (ultralow doses of antibodies to S100 protein) exhibited neuroprotective activity in rats with experimental photochemical thrombosis of the prefrontal cortex. Proproten was more potent than standard neuroprotectors piracetam and vinpocetine in alleviating the signs of memory disorders produced by ischemic injury. Pathomorphological study of the damaged area confirmed the neuroprotective effect of Proproten.

Animals↗
PubMed2005

Early postnatal effects of noopept and piracetam on declarative and procedural memory of adult male and female rats.

We studied the effect of a new nootropic dipeptide Noopept and reference nootropic preparation piracetam injected subcutaneously on days 8-20 of life on learning of alternative feeding response in a 6-arm-maze in male and female rats. Early postnatal administration of Noopept disturbed the dynamics of learning by parameters of declarative and procedural memory. Piracetam impaired learning by parameters of procedural, but not declarative memory (only in males). Both preparations decreased the ratio of successfully learned males (but not females). The observed effects were not associated with changes in locomotor activity.

Animals↗
PubMed2005

Neuroprotective effects of afobazol in experimental cerebral hemorrhage.

The study of novel selective anxiolytic afobazol on rats with experimental intracerebral post-traumatic hematoma (cerebral hemorrhage) demonstrated its efficiency in a dose of 5 mg/kg applied by a single or repeated administration for 2 weeks. The preparation significantly decreased the incidence of neurological disturbances in most rats (pareses, paralyses, convulsive movements, lateral posture). The therapeutic course of afobazol improved survival rate. Afobazol improved learning and memory in rats with cerebral hemorrhage in the conditioned passive avoidance test and positively affected motor activity in the open field test, which was documented by significant increase in total motor activity indices. The effects of afobazol were more pronounced after course treatment.

Animals↗
PubMed2005

[Functional brain activity in patients with Parkinson's disease during amantadin-sulfate therapy].

An investigation of bioelectrical brain activity in 32 patients with akinetic-rigid and trembling-rigid forms of Parkinson's disease was conducted before and after treatment with amantadin-sulfate on the basis of spectral-coherent EEG analysis. Comparing to controls, EEG deviations, mainly related to the main rhythm, were observed in 93.75% patients. Symptoms stabilization augmented EEG disorganization emerging in diffused spikes and sharp theta- and alpha-waves. The presence of paroxysmal activity in the form of synchronic bilateral groups of theta-waves and/or beta-waves was detected in 11 out of 32 patients, with paroxysmal activity of theta-waves being more evident in patients with a trembling PD form. In the group of patients with post treatment positive dynamics, EEG spectrum power increased in the range of alpha-beta-waves. Significant differences were mainly found in the range of beta-activity in frontal-parietal-occipital leads of the left hemisphere. The coherent analysis of EEG revealed that an amantadin-sulfate course resulted in normalization of space organization of biopotentials at the expense of a decrease of pathologically high indications of coherency for the majority of intra- and interhemisphere pairs of leads in alpha-, beta- and theta-ranges. In those regions, where the spectrum power increased in the same range, a significant decrease of the coherency indices was detected for inter hemispheric frontal-frontal, frontal-parietal and frontal-occipital leads and intracortical long connections of the left hemisphere. In amantadin-sulfate non-responders, the changes of EEG spectrum and coherency were insignificant.

Adult↗
PubMed2005

[Perspective technologies for drug design].

The review present the literature data and the authors findings on perspective technologies for design of active chemical and natural compounds based on small molecules for highly specific therapy and correction of a wide variety of pathophysiological conditions in humans, that show overlapping development processes and have common mediators. The following strategies are discussed: chemogenomics strategy using computer screening libraries for generating of small molecule compounds with advantageous properties; strategy of chemokine network that provide control of many processes, from immunosurveillance to inflammation and from viral infections to cancer; strategy of using cytochrome P450 enzymes that guarantee maximum bioavailability of drugs and prevent their interaction and toxic effect; strategy of using superoxide dismutase enzymes (SOD) correcting superoxide anions overproduction in tissue injury and inflammation, from ischemia, organ transplantation to AIDS and cancer; strategy of telomer maintenance directed to anticancer and antiviral therapy as well as to correction of the aging processes; and strategy of short interfering RNAs capable to induce intracellular immunity to antigens of various origin.

Chemokines↗
PubMed2004

[Changes of the EEG capacity observed in certain pathologies of the central nervous system and in pain].

Published data on changing spectra of electroencephalograms (EEG), as observed in different pathological hypoxic conditions (hypoxia, ischemia of the brain, aging) were analyzed; changing EEG spectra were experimentally studied in pain. The EEG changes were found to be identical in all cases. At the very beginning of a pathological factor onset, there was an increasing dominating peak of the EEG spectrum (or, the beta2-frequency range was going up--stage I). Then, the spectral distribution began to shift gradually to the low-frequency region: the frequency-predominant rhythm was slowing down; the slow-wave region was increasing and the fast-wave EEG part (II, III) was decreasing. Affections in pain fit the limits of I and II and, sometimes, III stages. In hypoxia and ischemia, a new stage of changes (IV) developed later: there emerged, in EEG, a peculiar high-amplitude rhythmic "burst-type" activity, which preconditioned a specific pattern of the EEG spectrum (the discussed stage is hard to detect in aging). The above stage is critical for the body. The total EEG capacity sharply dropped after its onset in hypoxia, ischemia and aging and the bioelectric activity was made up only of scanty slow waves (V). The described changing EEG spectra develop at an increasing total spectrum capacity (hypoxia), at capacity decrease (ischemia and aging) or it does not change altogether (pain). The homogeneous changes of EEG spectra in the above pathophysiological conditions make it possible to conclude that they denote a gradual progression of a change in brain functioning. It was suggested that such change is related with a slowing general velocity in brain functioning.

Animals↗
PubMed2004

[Clinico-neurophysiologic and experimental study of the peculiarities of adamantan-sulphate treatment in Parkinson's disease].

An experimental investigation of parkinsonism in rats and patients with initial forms of Parkinson's disease was performed by using methods of electromyography and electroneuromyography. Neurophysiologic peculiarities of reorganization of peripheral neuromotor apparatus and criteria for treatment efficacy were detected. The results obtained in the study allowed evaluating of an adequacy of adamantan-sulphate therapy either in the animal experiments and in patients with Parkinson's disease.

Aged↗
PubMed2003

Pharmacological activity of phenazepam and flunitrazepam in ultralow doses.

Experiments on male outbred albino rats showed that benzodiazepine tranquilizers phenazepam and flunitrazepam in ultralow doses (10(-9)-10(-15) mol/kg) produced an anxiolytic effect in the conflict situation test. This effect was not accompanied by myorelaxing and sedative side effects typical of standard doses of tranquilizers.

Animals↗
PubMed2003

Antidepressant properties of Proproten and amitriptyline: comparative experimental study.

Antidepressant properties of Proproten (antibodies to S100 protein in ultralow doses) were studied on outbred albino rats. The animals were subjected to the Porsolt's test of behavioral helplessness and Nomura's test of forced swimming in a reservoir with freely rotating wheels. Proproten in a dose of 2.5 ml/kg produced a strong antidepressant effect. It was observed after single and repeated (5 days) peroral treatment with the preparation. Proproten decreased the immobility time (Porsolt's test) and increased the number of wheel turns (Nomura's test). The activity of Proproten compared well with the standard preparation amitriptyline. As differentiated from amitriptyline, Proproten did not produce the sedative effect.

Amitriptyline↗
PubMed2003

Anxiolytic effect of Proproten under conditions of punished and unpunished behavior.

The anxiolytic effect of Proproten containing potentiated antibodies to brain-specific S100 protein (2.5 ml/kg) in male outbred albino rats was studied under conditions of punished (Vogel's conflict situation with pain stimulation) and unpunished behavior (elevated plus-maze and open-field tests). Proproten significantly increased the incidence of punished drinking in the conflict situation with pain stimulation, number of entries, and time spent in the open arms of the elevated plus-maze and decreased the rate of defecation and urination. In the open-field test Proproten induced entries of rats into the center of an illuminated area. Proproten was efficient after single administration and course of treatment (2 times a day, 5 days). These results show that Proproten produces the anxiolytic effect under conditions of punished and unpunished behavior.

Animals↗
PubMed2003

GABAergic system in the anxiolytic effect of Proproten: experimental study.

The medicinal preparation Proproten contains ultralow doses of antibodies to S100 protein that acts as an important regulator of integrative activity in the brain and synaptic processes. Intracerebroventricular administration of Proproten, diazepam, and mexidol in doses of 2.5 ml/kg, 2 mg/kg, and 100 mg/kg, respectively, produced a strong anxiolytic effect on male outbred rats in the conflict situation and markedly increased the incidence of punished drinking. Antagonists of GABAergic transmission bicuculline (GABAA receptor blocker) and picrotoxin (chlorine channel blocker) produced the pro-conflict anxiogenic effect, which was accompanied by a decrease in the number of punished drinking in control animals. The anti-conflict effect of Proproten was less pronounced during blockade of GABAA receptors or chlorine channels. Bicuculline and picrotoxin similarly modulated the anxiolytic effect of diazepam and mexidol. Our results suggest that the GABAergic system plays a role in the anxiolytic effect of diazepam, mexidol, and Proproten.

Animals↗
PubMed2003

Effects of phenazepam in ultralow doses on bioelectric activity of the brain and behavior of rats in various models of anxiety.

Phenazepam in ultralow doses produced an anxiolytic effect on male outbred albino rats in the conflict situation and elevated plus-maze models and inhibited theta-activity in EEG, which is typical of tranquilizers. As differentiated from standard doses, phenazepam in this concentration did not affect other frequency bands. Our results suggest that phenazepam in ultralow doses acts as the anxioselective tranquilizer.

Animals↗
PubMed2002

Effect of nooglutil on benzodiazepine withdrawal syndrome and binding of 3H-spiperone with D2 receptors in rat striatum.

A new nootropic preparation nooglutil (N-(5-oxynicotinoyl)-L-glutamic acid), a positive modulator of AMPA receptors for glutamate, administered intraperitoneally in a dose of 70 mg/kg reduced anxiety of rats in the Vogel conflict test after 24-h withdrawal from chronic diazepam treatment (4 mg/kg intraperitoneally for 45 days). Nooglutil (5 nM-750 microM) had no effect on in vitro binding of (3)H-spiperone in intact rats. Systemic administration of 50 mg/kg nooglutil in vivo increased the dissociation constant and density of D(2)receptors. Increasing the dose to 100 mg/kg abolished this effect. Our findings suggest that nooglutil produces an indirect effect on the brain dopaminergic system under normal and pathological conditions and this effect is probably mediated via the glutamatergic system.

Animals↗
PubMed2002

[Antioxidant Mexidol premedication of patients with periodontitis during antihomotoxic therapy].

The tranquilizing effect of antioxidant mexydol on 95 patients with chrconic generalized parodontitis against a background of various somatic diseases was evaluated. The anxiety and the efficiency of premedication were accessed according to Korach's and Spilberger's scales and according to the special psychological questionnaire. The quantitative characteristics of premedication were given baised on the psychological tests results. There was registered a definite improvement of health characteristics and of patient's mood in comparison to the initial input data as well as lower lever of their situational anxiety. This proves the tranquilizing effect of premedication with mexidol (5% amp.). The most evident dynamics of these changes can be observed among patients suffering from high initial anxiety level. The findings of the study are based on more than 2 year old history of treatment of 30 patients with traumel. 21 patients suffering from disfunction of the nervous system were given some comprehensive treatment (traumel locally orally and mexidol in injections). The clinical effect resulted in emotional stabilization of patients and reduced the time needed for their clinical treatment. The medicines were combined. No side effects were observed.

Adolescent↗
PubMed2001

Proline-containing dipeptide GVS-111 retains nootropic activity after oral administration.

Experiments on rats trained passive avoidance task showed that N-phenyl-acetyl-L-prolyl-glycyl ethyl ester, peptide analog of piracetam (GVS-111, Noopept) after oral administration retained antiamnesic activity previously observed after its parenteral administration. Effective doses were 0.5-10 mg/kg. Experiments on a specially-developed model of active avoidance (massive one-session learning schedule) showed that GVS-111 stimulated one-session learning after single administration, while after repeated administration it increased the number of successful learners among those animals who failed after initial training. In this respect, GVS-111 principally differs from its main metabolite cycloprolylglycine and standard nootropic piracetam.

Administration, Oral↗